US stock · figures in US dollars · scored on full-year results
Biogen Biogen Inc.
Biogen scores 53/100 on fundamentals: in the top 50% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Business Strength (13/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
A financially strong, expensively priced stock, but business strength needs attention.
Nearby peers
Ranks #32 of 60 in Healthcare by score
One-Minute Summary
Why Biogen scores 53
A financially strong, expensively priced stock, but business strength needs attention.
Business StrengthLowest pillar
13Why 13?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.
Profit fell about 70.1% from where it was 4 years ago: the boom has cooled off.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 154.1% over the last 8 quarters: customers keep spending more with this company.
The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.
Financial Safety
100Why 100?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings have stayed roughly level: manageable, as long as profits stay healthy.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
75Why 75?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price Fairness
17Why 17?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 64.4% over the past year.
Risk
50Why 50?
No data: Quarterly Consistency
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Biogen (BIIB) scores 53/100 (Okay) on Score Your Stock's educational fundamentals model: in the top 50% of 503 scored S&P 500 stocks.
Its strongest pillar is Financial Safety (100/100); its weakest is Business Strength (13/100).
Biogen ranks #32 of 60 scored Healthcare stocks on Score Your Stock.
Biogen (BIIB) has not paid a dividend in the last 12 months.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy BIIB. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Biogen (BIIB) is a Healthcare company (Drug Manufacturers - General). On Score Your Stock's fundamentals check, it scores 53/100, rated Okay. Its biggest strength is Financial Safety (100/100); its main watch-out is Business Strength (13/100). Shares currently cost about 108 years of its current profit to buy (P/E 107.8×). Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/biib-biogen
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 10.3b | US$ 347.5m | US$ 2.9b | US$ 2.5b | US$ -388.8m | US$ 1.3b | US$ 8.4b | US$ 800.0m | US$ 18.8b | US$ 7.3b | US$ 3.9b | US$ 32.1b | US$ 13.2b | US$ 2.4b | - | 2% | 3% | 0.4× | 1.9× | 5.0× | - | - | - |
| 2025 | US$ 9.9b | US$ 1.3b | US$ 2.2b | US$ 2.0b | US$ -235.4m | US$ 3.0b | US$ 6.6b | - | US$ 18.3b | US$ 9.0b | US$ 3.3b | US$ 29.4b | US$ 11.2b | US$ 2.2b | US$ 0.0m | 7% | 13% | 0.4× | 2.7× | 6.8× | 0% | 20.2× | 1.4× |
| 2024 | US$ 9.7b | US$ 1.6b | US$ 2.9b | US$ 2.5b | US$ -359.8m | US$ 2.4b | US$ 6.6b | US$ 1.7b | US$ 16.7b | US$ 7.5b | US$ 5.5b | US$ 28.0b | US$ 11.3b | US$ 2.5b | US$ 0.0m | 10% | 17% | 0.4× | 1.4× | 8.6× | 0% | 13.6× | 1.3× |
| 2023 | US$ 9.8b | US$ 1.2b | US$ 1.5b | US$ 1.2b | US$ -311.4m | US$ 1.0b | US$ 7.3b | US$ 150.0m | US$ 14.8b | US$ 6.9b | US$ 3.4b | US$ 26.8b | US$ 12.0b | US$ 2.5b | US$ 0.0m | 8% | 12% | 0.5× | 2.0× | 6.3× | 0% | 32.3× | 2.5× |